EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the appointment of Miguel Fernández Alcalde as President of EMD Serono.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210746046/en/

Miguel Fernández Alcalde, President of EMD Serono (Photo: Business Wire)

“Miguel’s exceptional leadership and proven track record of success will be instrumental in further strengthening our position in the U.S., a critical market for advancing our global Healthcare strategy,” said Peter Guenter, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare. “Today, we deliver important therapeutic options to more than 150,000 oncology, multiple sclerosis and fertility patients in the U.S. Miguel’s appointment underscores our clear commitment to these patients we serve, to our employees, and to consistently deliver outstanding results.”

For the last 18 months, Mr. Fernández Alcalde has served as Chief Operating Officer for EMD Serono. Previously, he served as Chief of Staff for Peter Guenter, CEO Healthcare, and as Head of Global Business Excellence & Innovation. He has also held leadership roles as General Manager in Finland and Spain for Merck KGaA, Darmstadt, Germany. Mr. Fernández Alcalde joined Merck KGaA, Darmstadt, Germany, in 2014.

Mr. Fernández Alcalde holds a Bachelor’s Degree in Pharmacy from the University Complutense in Madrid, a Master of Business Administration from the University of Alcalá de Henares, and a Master’s Degree in Management from IESE business School.

“I am honored to take on this new responsibility and continue EMD Serono’s commitment to improving the lives of patients with unmet medical needs,” said Mr. Fernández Alcalde. “I look forward to leading our teams and advancing the work that has positioned EMD Serono for continued growth in the US biopharmaceutical industry.”

Mr. Fernández Alcalde succeeds Chris Round, who has made the decision to retire from the company. During Mr. Round’s eight years with the company, first leading Europe and Middle East-Africa, then International and Core Franchises, and for the last three and a half years as President of EMD Serono, he has helped to lead the company through numerous launches, strong profitable growth and broad, deep talent development.

“Chris has been invaluable in positioning EMD Serono for success in the U.S. over the last several years,” said Guenter. “His leadership, strategic vision, and commitment have played a pivotal role in advancing our business growth and our impact for the patients we serve, our customers and for our employees. We are deeply grateful for his contributions and wish him the very best in his future endeavors.”

Mr. Fernández Alcalde will be based in Boston, MA at EMD Serono’s Seaport offices.

About EMD Serono, Inc.

EMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada - aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono’s global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. www.emdserono.com.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210746046/en/